Exabis Library
Welcome to the e-CCO Library!
P421: Effects of combination therapy in inflammatory bowel disease: how long should we keep concomitant immunomodulators?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P421: Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P421: SER-287, an investigational microbiome therapeutic, induces remission and endoscopic improvement in a placebo-controlled, double-blind randomised trial in patients with active mild-to-moderate ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P421: Skin side effects of biologic therapy and systemic drugs in patients with inflammatory bowel diseases
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P421: Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P422: COVID 19 infection in IBD patients treated with biologic therapy-experience from tertiary center in Serbia
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P422: How achievable are the STRIDE-II treatment targets in real-world practise and do they affect outcome?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P422: Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assay
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P422: Risks and clinical features of active tuberculosis developed in patients with inflammatory bowel disease receiving anti-tumour necrosis factor therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P422: Transition from intravenous to subcutaneous infliximab and vedolizumab: adherence, satisfaction and safety profile in a cohort of patients with Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P423 NF-kB as a prognostic marker of response to biologic therapy in children with IBD
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P423: Azathioprine still remains the first step-up therapy in patients with Inflammatory Bowel Disease in low-middle income countries.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P423: Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P423: Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCU
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P423: Paediatric Crohn’s disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM